Angiopro GmbH - Medical Imaging Europe Solutions/Service Company
healthcaretechoutlook

Angiopro GmbH: Demystifying Patient Screening for Cardiac Procedures

Benjamin Joas Rieck, CEO, Angiopro GmbHBenjamin Joas Rieck, CEO, Angiopro GmbH
In March of 1986, when French physician Jacque Puel successfully implemented the world’s first coronary stent into a patient, the world of interventional cardiology was primed to expand the horizons of how doctors treat cardiac problems. Fast-forward 35 years and the current cardiology space is ripe with highly sophisticated diagnostic and interventional offerings that are continuing the efficacy of cardiac device implantation to new heights. However, even with all these years of innovation, the cardiology space is still considered a laggard with respect to its screening process due to its invasive, cumbersome, and expensive nature. This is because most cardiologists still follow legacy approaches due to a lack of better and, more importantly, safer alternatives to patient screening.

Addressing this need with its suite of innovative patient screening software solutions capable of helping doctors accurately choose the best way to approach their interventional and surgical procedures is Germany-based Angiopro GmbH. Apart from its role in the cardiovascular patient screening sector, the company has an expansive partner and distribution network across Europe’s DACH region and other locations around the globe. “With our screening software, cardiologists and surgeons can effectively assess whether a patient is in need of surgical or percutaneous intervention and efficiently identify the best access route for stent placement based on a patient’s individual condition,” says Benjamin Joas Rieck, CEO at Angiopro GmbH.

Founded in 1999 by Benjamin’s father, Hanns-Joachim Rieck, Angiopro GmbH is a family-owned business that was originally established as a classic distributor of cardiovascular medicine but soon became a driver of innovation in the cardiovascular care sector. Over the years, the company developed key partnerships with top players in cardiovascular healthcare IT and device manufacturers. “As a leading distributor, we have been connecting physicians and highly sophisticated care products for over three decades, and with our patient screening software, we hope to more actively drive better patient outcomes,” adds Rieck.

The company’s patient screening software suite comprises two offerings, namely, the CAAS® and 3mensio® solutions. Unlike the conventional method of patient screening that involves surgical invasion and patient medication, the CAAS® and 3mensio® software leverage intuitive graphical user interfaces and intelligent workflows to help physicians gain critical insights into a patient’s cardiac state.


With our screening software, cardiologists and surgeons can effectively assess whether a patient is in need of surgical or percutaneous intervention and efficiently identify the best access route based on a patient’s individual condition

Angiopro GmbH’s CAAS® software leverages its state-of-the-art quantitative coronary analysis capability, which accurately measures coronary artery dimensions and quantifies stenosis for single and bifurcated vessels to help surgeons ensure the safest way to approach a coronary procedure. With the collected measurements, surgeons can easily choose the optimal balloon and stent size for the particular patient. Alternatively, with 3mensio®, physicians can quickly and accurately visualize and analyze the vasculature, aortic, mitral and tricuspid valve, and left atrial appendage. Once this is done, the solution then generates dedicated reports for each coronary facet, which helps doctors gain a deeper understanding of a patient’s pathology and, thus, drive a more precise procedure. Above all, both software solutions support all DICOM formats for medical imaging and can seamlessly be run on any modern Windows computer without the need for expensive specialized hardware.

Further discussing his company’s core competencies, Rieck mentions how Angiopro GmbH not only bridges the gap between physicians and state-of-the-art treatment avenues but also leverages its unparalleled support services to help hospitals ensure 100 percent uptime. “For software offerings, downtime can be critically damaging. Therefore, our Healthcare-IT team is always available to help our users make the most of their implementations with engaging training regimes and live postimplementation support,” states Rieck.

Concurrently, Angiopro GmbH also supports emerging cardiovascular technology, and IT companies scale their operations efficiently through its AngioConsult GmbH and AngioInvest Ltd. programs. “AngioConsult GmbH allows us to support growing startups in the CVS space by helping them validate their product and enhancing their launch. On the other hand, AngioInvest Ltd. enables us to actively finance innovative new firms as well as offer our wide distribution infrastructure to boost their growth,” explains Rieck.

Looking ahead, Angiopro GmbH is poised to expand out of its pre-procedure planning focus and develop procedural software powered by AI that can help physicians gain critical insights on a patient’s current cardiac state in real-time at the operating table. In pursuit of this, the company is planning to launch a software offering in the upcoming months. From a geographical standpoint, Angiopro GmbH aims to grow its budding footprint in the East European territories and develop highly competent sales networks in territories outside the DACH region. To conclude, Rieck reiterates the ethos of Angiopro GmbH, “At the heart of our business is our family-owned gene that will always drive us to continually innovate our products with an aim to help growing businesses make their mark through the creation of better patient outcomes.”

Share this Article:
Top 10 Medical Imaging Solution Companies in Europe - 2021
Angiopro GmbH

Company
Angiopro GmbH

Headquarters
Speyer, Germany

Management
Benjamin Joas Rieck, CEO , Angiopro GmbH

Description
Angiopro offers state-of-the-art patient screening software for CVS procedures that enables enhanced efficiencies and drive better patient outcomes. The company's patient screening software suite comprises two offerings, namely, the CAAS® and 3mensio® solutions. Unlike the conventional method of patient screening that involves surgical invasion and patient medication, the CAAS® and 3mensio® software leverage intuitive graphical user interfaces and intelligent workflows to help physicians gain critical insights into a patient's cardiac state. As a leading distributor, the company has been connecting physicians and highly sophisticated care products for over three decades, and with its patient screening software, they hope to more actively drive better patient outcomes